CCR6 and neoplasm: The potential to inhibit tumour growth by targeting VLCs is illustrated by our studies with CCR6-immunotoxins: Tumours injected in the presence of anti-CCR6 antibodies bound to saporin, a ribosomal-inactivating protein, grew 2.6-fold less than tumours injected with an isotype control antibody.